Efficacy of Tivozanib

On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor tivozanib for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after receiving two or more prior systemic therapies. The approval was based on theTIVO-3 trial. The primary efficacy outcome measure was progression-free survival (PFS), and other efficacy endpoints were overall survival (OS) and objective response rate (ORR).

In this trial, tivozanib was compared with sorafenib in patients with relapsed or refractory advanced renal cancer who had received two or three prior systemic therapies, including at least one VEGFR kinase inhibitor, but not sorafenib or tivozanib, and who were kept on the drug until disease progression or unacceptable toxicity. The study results showed that the median PFS in the tivozanib group was 5.6 months, while that in the sorafenib group was 3.9 months. The median OS of the Tivozanib group and the sorafenib group were 16.4 and 19.2 months respectively. The ORR of the Tivozanib group was 18%, and the ORR of the sorafenib group was 8%.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.